International Assets Investment Management LLC Buys 58,299 Shares of Repligen Co. (NASDAQ:RGEN)

International Assets Investment Management LLC lifted its stake in Repligen Co. (NASDAQ:RGEN) by 18,449.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 58,615 shares of the biotechnology company’s stock after buying an additional 58,299 shares during the period. International Assets Investment Management LLC owned approximately 0.10% of Repligen worth $10,539,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Signaturefd LLC increased its stake in shares of Repligen by 44.1% in the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock worth $45,000 after buying an additional 86 shares during the period. First Horizon Advisors Inc. increased its position in shares of Repligen by 14.8% in the third quarter. First Horizon Advisors Inc. now owns 675 shares of the biotechnology company’s stock valued at $107,000 after acquiring an additional 87 shares during the period. Daiwa Securities Group Inc. boosted its holdings in shares of Repligen by 3.2% during the third quarter. Daiwa Securities Group Inc. now owns 3,200 shares of the biotechnology company’s stock worth $509,000 after purchasing an additional 100 shares during the period. State of Michigan Retirement System grew its stake in shares of Repligen by 0.8% in the fourth quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock worth $2,239,000 after purchasing an additional 100 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its holdings in Repligen by 2.5% during the 3rd quarter. Teacher Retirement System of Texas now owns 4,098 shares of the biotechnology company’s stock valued at $652,000 after purchasing an additional 101 shares during the period. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on RGEN shares. JPMorgan Chase & Co. dropped their price objective on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday. KeyCorp raised their price target on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Finally, Stifel Nicolaus boosted their price objective on shares of Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $197.75.

Repligen Stock Performance

Shares of Repligen stock opened at $167.05 on Monday. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13. The firm has a market capitalization of $9.33 billion, a P/E ratio of 668.23, a P/E/G ratio of 5.46 and a beta of 1.03. The company has a current ratio of 6.35, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26. The business has a fifty day simple moving average of $180.81 and a two-hundred day simple moving average of $174.32.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The business had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. During the same period last year, the business earned $0.64 earnings per share. The company’s revenue was down 17.1% on a year-over-year basis. On average, equities analysts forecast that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Insider Activity at Repligen

In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the sale, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Karen A. Dawes sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the transaction, the director now owns 87,367 shares in the company, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. Insiders sold a total of 25,597 shares of company stock valued at $5,039,532 in the last 90 days. Corporate insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.